CA3102630A1 - Cyclic peptide compounds and methods of use thereof - Google Patents

Cyclic peptide compounds and methods of use thereof Download PDF

Info

Publication number
CA3102630A1
CA3102630A1 CA3102630A CA3102630A CA3102630A1 CA 3102630 A1 CA3102630 A1 CA 3102630A1 CA 3102630 A CA3102630 A CA 3102630A CA 3102630 A CA3102630 A CA 3102630A CA 3102630 A1 CA3102630 A1 CA 3102630A1
Authority
CA
Canada
Prior art keywords
seq
compound
nhac
cancer
protecting group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3102630A
Other languages
English (en)
French (fr)
Inventor
Mark Mclaughlin
Lori Hazlehurst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Modulation Therapeutics Inc
Original Assignee
Modulation Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modulation Therapeutics Inc filed Critical Modulation Therapeutics Inc
Publication of CA3102630A1 publication Critical patent/CA3102630A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3102630A 2018-06-05 2019-06-05 Cyclic peptide compounds and methods of use thereof Pending CA3102630A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862680904P 2018-06-05 2018-06-05
US62/680,904 2018-06-05
PCT/US2019/035652 WO2019236747A2 (en) 2018-06-05 2019-06-05 Cyclic peptide compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3102630A1 true CA3102630A1 (en) 2019-12-12

Family

ID=68769580

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3102630A Pending CA3102630A1 (en) 2018-06-05 2019-06-05 Cyclic peptide compounds and methods of use thereof

Country Status (5)

Country Link
US (2) US12060438B2 (https=)
EP (1) EP3801592A4 (https=)
JP (1) JP2021527123A (https=)
CA (1) CA3102630A1 (https=)
WO (1) WO2019236747A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117466788A (zh) * 2023-10-30 2024-01-30 吉尔多肽生物制药(大连市)有限公司 一种Nα-叔丁氧羰基-L-半胱氨酸的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2328603A4 (en) * 2008-08-18 2013-01-02 Univ Maryland APF DERIVATIVES AND USE METHOD
EP2547693B1 (en) * 2010-03-19 2015-03-11 H. Lee Moffitt Cancer Center & Research Institute Integrin interaction inhibitors for the treatment of cancer
US20150071918A1 (en) * 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer
US20140322227A1 (en) 2013-04-26 2014-10-30 H. Lee Moffitt Cancer Center & Research Institute, Inc. Peptides for treatment of bone deficiency and autoimmune disorders
US10011635B2 (en) * 2013-09-27 2018-07-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
US10197575B2 (en) * 2014-03-31 2019-02-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stabilized peptoid-peptide hybrids and uses thereof

Also Published As

Publication number Publication date
JP2021527123A (ja) 2021-10-11
EP3801592A2 (en) 2021-04-14
US20210347826A1 (en) 2021-11-11
WO2019236747A3 (en) 2020-01-23
WO2019236747A2 (en) 2019-12-12
EP3801592A4 (en) 2022-04-27
US20250136642A1 (en) 2025-05-01
US12060438B2 (en) 2024-08-13

Similar Documents

Publication Publication Date Title
JP7813098B2 (ja) 生物学的に活性な化合物を含む剛性間隔基を有するポリマー
JP7358342B2 (ja) 新規なグルタミンアンタゴニストおよびそれらの使用
US10954257B2 (en) Prodrugs of glutamine analogs
JP2018503653A (ja) がんを処置するための併用療法
EP4308124A1 (en) Therapeutic regimens of an inhibitor of the enzymatic activity of brg1 and brm
WO2014197854A1 (en) Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
EP3394047B1 (en) Deuterated compounds for treating cancer and compositions and methods thereof
JP2019069969A (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
US20250136642A1 (en) Cyclic peptide compounds and methods of use thereof
ES2734425T3 (es) Dendrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes
US11712435B2 (en) Mebendazole prodrugs with enhanced solubility and oral bioavailability
US20220289686A1 (en) Compositions of nrf2 inhibiting agents and methods of use thereof
US8753605B2 (en) Imaging probes, methods of making imaging probes, and methods of imaging
US20250099408A1 (en) Improved suramin methods and compositions
EP4335452A1 (en) Pharmaceutical composition for enhancing anticancer effect of anticancer drug
JP2022023033A (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
JP5581200B2 (ja) シチジン誘導体及びカルボプラチンを含有する抗腫瘍剤
EP4725507A1 (en) Polypeptide conjugate, pharmaceutical composition containing polypeptide conjugate and use thereof
EP4720084A1 (en) Tumor redox-activated 6-thiopurine containing dimer compounds
HK40038916A (en) Antitumor agent, antitumor effect potentiator and antitumor kit

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260129

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260204

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260205